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Edited by Sandro SonninoAbstract Chemotaxis induction is a major eﬀect evoked by
stimulation of the chemokine receptor CXCR4 with its sole li-
gand CXCL12. We now report that treatment of CHP-100 hu-
man neuroepithelioma cells with the glucosylceramide synthase
(GCS) inhibitor DL-threo-1-phenyl-2-hexadecanoylamino-3-
pyrrolidino-1-propanol inhibits CXCR4-dependent chemotaxis.
We provide evidence that the phenomenon is not due to unspeciﬁc
eﬀects of the inhibitor employed and that inhibition of GCS nei-
ther aﬀects total or plasmamembrane CXCR4 expression, nor
CXCL12-induced Ca2+ mobilization. The eﬀects of the GCS
inhibitor on impairment of CXCL12-induced cell migration tem-
porally correlated with a pronounced downregulation of neutral
glycosphingolipids, particularly glucosylceramide, and with a de-
layed and more moderate downregulation of gangliosides; more-
over, exogenously administered glycosphingolipids allowed
resumption of CXCR4-dependent chemotaxis. Altogether our re-
sults provide evidence, for the ﬁrst time, for a role glyco-
sphingolipids in sustaining CXCL12-induced cell migration.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Neuroepithelioma1. Introduction
Activation of the chemokine receptor CXCR4 by its unique
physiological ligand CXCL12 (stromal cell derived factor-1,
SDF-1) evokes pleiotropic eﬀects on a broad range of target
tissues and fulﬁls a variety of functions both during develop-Abbreviations: PPPP, DL-threo-1-phenyl-2-hexadecanoylamino-
3-pyrrolidino-1-propanol; GCS, glucosylceramide synthase; GSL,
glycosphingolipid; GlcCer, glucosylceramide; GalCer, galactosylcera-
mide; LacCer, lactosylceramide; Gb3, globotriaosylceramide; C8-
GlcCer, D-Glucosyl-b1-1 0-N-octanoyl-D-erythro-sphingosine; C8-Lac-
Cer, D-Lactosyl-b1-10-N-octanoyl-D-erythro-sphingosine; HPTLC,
high-performance thin layer chromatography; PBS, phosphate buf-
fered saline; FACS, ﬂuorescence-activated cell sorting
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doi:10.1016/j.febslet.2007.05.003ment and adulthood [1]. A prominent eﬀect brought about
by CXCR4 activation is chemotaxis induction: by this mecha-
nism, activation of the CXCL12/CXCR4 axis is involved, for
instance, in proper homing of haemato-/lympho-poietic cells
[2], in the cytoarchitectural maturation of certain districts of
the central nervous system [2,3], as well as in mobilization of
cellular elements during the inﬂammatory response [4]. Re-
cently, an important role for the CXCL12/CXCR4 axis has
also been proposed in connection with tumor progression: in
fact, there is evidence that expression of CXCR4 by tumor
cells may direct their metastatization to CXCL12 producing
sites [5–7].
CXCR4 is a seven-transmembrane-domain receptor coupled
to heterotrimeric proteins of the Gi family and its engagement
by CXCL12 evokes activation of a multiplicity of signalling
pathways: among these, activation of phosphoinositide 3-ki-
nase and/or extracellular signal-regulated kinases have been
shown to provide key events for chemotaxis induction in a
variety of cell systems [3,5,8–10]. Notably, evidence has been
provided that signalling through CXCR4 may be sensitive to
the receptor lipid environment. In particular, it has been
shown that cholesterol may be crucial for maintaining a recep-
tor conformation with high aﬃnity for its ligand [11]; more-
over, it has been reported that CXCR4 signalling, at least in
the context of chemotaxis induction, may require receptor
recruitment into lipid rafts [12].
Glycosphingolipids (GSLs) are major components of cell
membranes and of lipid rafts as well; nevertheless, at present,
the issue of possible functional relationships between the
CXCR4/CXCL12 axis and GSLs, in the context of cell migra-
tion, has been fairly disregarded. This issue has been herein ad-
dressed having as an experimental model the human
neuroepithelioma cell line CHP-100 [13]: CXCR4, in fact, is
constitutively expressed by CHP-100 cells [14] and, in this sys-
tem, it has been reported to mediate CXCL12-induced chemo-
taxis [8].2. Materials and methods
2.1. Materials
Material for cell culture, Sephadex G-50 and all natural lipids were
from Sigma. DL-threo-1-phenyl-2-hexadecanoylamino-3-pyrrolidino-
1-propanol (PPPP) was from Calbiochem–Novachem. D-Glucosyl-blished by Elsevier B.V. All rights reserved.
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b1-1 0-N-octanoyl-D-erythro-sphingosine (C8-LacCer) were from Avan-
tiPolar. Silica gel 60 high-performance thin layer chromatography
(HPTLC) plates were from Merck. CXCL12 was from Peprotech.
The anti-CXCR4 antibody (C20) was from Santa Cruz Biotechnology.
The R-phycoerythrin-conjugated mouse anti-human CXCR4 mono-
clonal antibody was from Pharmingen. The Apotest FITC Kit was
from Nexins Research B.V. The chemiluminescence ECL detection
system was from Amersham. Fura-2/AM was from Molecular Probes.
2.2. Cell culture
Cells were grown at 37 C in RPMI 1640 medium, supplemented
with 10% heat-inactivated fetal calf serum, 2 mM glutamine, 100
i.u./ml penicillin and 100 lg/ml streptomycin, in a humidiﬁed atmo-
sphere with 5% CO2. PPPP, C8-GlcCer and C8-LacCer were adminis-
tered to cells from dimethylsulfoxide stock solutions (1 mM, 40 mM
and 40 mM, respectively); CXCL12 and ganglioside GM2 were admin-
istered from aqueous stock solutions (12.5 lM and 50 mM, respec-
tively).
2.3. Lipid analysis
Control and PPPP-treated cells were washed twice with phosphate
buﬀered saline (PBS), pH 7.4, trypsinized and pelleted at 600 · g for
5 min at 4 C. Lipids were extracted by the method of Folch et al.
[15]. For ganglioside separation, the Folch’s upper phase was dried un-
der vacuum, redissolved in distilled water and desalted by gel ﬁltration.
Gangliosides recovered in the void volume were dried under vacuum,
resuspended in chloroform/methanol (2:1, v/v), spotted onto HPTLC
plates, developed in chloroform/methanol/0.22% CaCl2 (60:40:9, v/v/
v) and visualized by staining with the resorcinol reagent [16]. For anal-
ysis of neutral GSLs and ceramide, the Folch’s lower phase was dried,
lipids resuspended in 0.1 M methanolic KOH, subjected to mild alka-
line hydrolysis for 1 h at 37 C and re-extracted by the Folch’s method.
Ceramide was resolved by developing samples in chloroform/acetic
acid (9:1, v/v) and visualized, after charring, with 3% cupric acetate
in 8% phosphoric acid [17]. For separation of neutral GSLs, samples
were developed in chloroform/methanol/water (65:25:4, v/v/v). In some
analyses, to achieve a better resolution between glucosyl- and galacto-
syl-ceramide, neutral GSLs were resolved on HPTLC plates dipped in
2.5% (w/v) methanolic boric acid and activated by heating at 110 C
for 30 min [18]. Neutral GSLs were visualized by the a-naphthol re-
agent [16]. For phospholipid analysis, aliquots of the Folch’s lower
phase were developed in chloroform/methanol/acetic acid/water
(60:27:8:2, v/v/v/v). Cholesterol was separated by developing aliquots
of the Folch’s lower phase in petroleum ether/diethyl ether (96:4,
v/v) for full plate length and, after drying, for half-length in the same
dimension, in petroleum ether/diethyl ether/formic acid (80:20:2, v/v/
v). Both phospholipids and cholesterol were visualized, after charring,
with 3% cupric acetate in 8% phosphoric acid [17]. Lipid quantitation
was performed by densitometric analysis, after HPTLC separation and
spot visualization as described above, using a computerized image pro-
cessing system (Gel-Pro Analyzer) and, when necessary, referring to
known amounts of authentic lipid standards developed along with
samples.2.4. Western Blot analysis
To monitor CXCR4 expression, control or PPPP-treated cells were
washed with PBS and directly lysed with hot SDS sample buﬀer. Equal
amounts of protein [19] from each sample were processed and analyzed
as previously reported [8].
2.5. Chemotaxis assay
Control and PPPP-treated cells were trypsinized, washed twice with
RPMI 1640 and plated (500000/ well) on 12 mm transwells (8 lm pore
size ﬁlters) in RPMI 1640, enriched with 0.5 lM PPPP, in the case of
PPPP-pretreated cells, and containing or not the glucosylceramide syn-
thase (GCS) inhibitor at the above-reported concentration, in the case
of control cells, as indicated in the text. C8-GlcCer (40 lM) or C8-Lac-
Cer (40 lM) or ganglioside GM2 (50 lM) were also added to the med-
ium, when indicated. The lower chambers contained RPMI 1640
medium enriched with 60 nM CXCL12 or vehicle (water). After 5 h
of incubation at 37 C, cells were treated with ice-cold 10% trichloro-
acetic acid for 5 min. Cells adhering to the upper side of the ﬁlter were
scraped oﬀ, while cells on the lower side were stained with a solutioncontaining 50% isopropanol, 1% formic acid and 0.5% (w/v) brilliant
blue R 250. Stained cells were counted in more than 20 ﬁelds with a
40· objective.2.6. Analyses by ﬂuorescence-activated cell sorting (FACS)
For evaluating membrane CXCR4 expression, control and PPPP-
treated cells were washed twice with RPMI 1640, trypsinized and cen-
trifuged at 600 · g for 5 min at 4 C. The pellets were washed twice
with PBS, resuspended in 1 ml of ﬂuorescence-activated cell sorting
(FACS) buﬀer (5% fetal bovine serum and 0.1% sodium azide in
PBS) and subdivided in two aliquots of 0.5 ml each. The two aliquots
were centrifuged at 600 · g for 5 min at 4 C; thereafter, one sample
was resuspended in 15 ll of FACS buﬀer containing the phycoery-
thrin-conjugated anti-CXCR4 antibody diluted 1:11, and the other
in 15 ll of FACS buﬀer alone (for autoﬂuorescence estimation). After
incubation at 4 C for 30 min, cells were pelleted, washed twice and
resuspended in FACS buﬀer. Samples were analyzed on a FACSCali-
bur (Becton-Dickinson, USA), with a CellQuest software. Cell viability
was estimated by dual staining with annexin V-FITC and propidium
iodide, using a commercially available Kit (Apotest FITC), according
to the manufacturer’s instructions.2.7. Ca2+ measurements
Control and PPPP-treated cells were incubated for 45 min at 37 C
in RPMI 1640 containing the membrane permeant dye Fura-2/AM
(4 lM). Fluorescence determinations were made using a conventional
system driven by Axon Imaging Workbench software (Axon Instr.).
All optical parameters and digital camera settings were maintained
throughout, to avoid non-homogeneous data. The changes in free
cytosolic Ca2+ concentration ([Ca2+]i) were expressed as DR (i.e. the
ratio between the images acquired with two excitation wavelengths,
340 nm and 380 nm, monitoring emission at 510 nm).3. Results
3.1. Long-term treatment of CHP-100 cells with PPPP induces
general GSL depletion and inhibits CXCL12-induced cell
migration but not Ca2+ mobilization
As a ﬁrst approach to our study, CHP-100 cells were cul-
tured for 5 d in the presence of the speciﬁc GCS inhibitor
PPPP (0.5 lM) [20], in order to achieve general GSL depletion;
the chemotactic response of GSL-depleted cells to CXCR4 was
then monitored and compared to that of control cells.
As shown in Fig. 1A, control CHP-100 cells displayed gan-
glioside species comigrating with GM3, GM2, GM1 and
GD1a standards (band multiplicity and slight migration shifts
likely reﬂect heterogeneous length of the ceramide mojeties);
notably, in cells cultured for 5 d in the presence of PPPP, the
levels of all the above-mentioned ganglioside species fell below
the detection limit of the staining method. Fig. 1B shows that
exposure of CHP-100 cells to 0.5 lM PPPP for 5 d also in-
duced a dramatic downregulation of the levels of major neutral
GSL species, namely glucosylceramide (GlcCer), lactosylcera-
mide (LacCer) and globotriaosylceramide (Gb3); moreover,
sustained GCS inhibition did not redirect GSL metabolism to-
ward galactosylceramide (GalCer) synthesis, as conversely ob-
served in other cell systems [21] (Fig. 1B).
Consistently with previous ﬁndings [20,22], we found that
ceramide levels were not signiﬁcantly increased in PPPP-trea-
ted cells (0.95 ± 0.30 lg/mg protein, n = 3) as compared to
controls (0.59 ± 0.14 lg/mg protein, n = 3); this was apparently
due to ceramide utilization for synthesis of sphingomyelin,
whose levels rose from 8.4 ± 0.7 lg/mg protein (n = 3), as ob-
served in control cells, to 20.1 ± 3.6 lg/mg protein (n = 3) in
PPPP-treated cells (P < 0.01 by Student’s t test). Most notably,
Fig. 1. Long-term treatment with PPPP downregulates GSLs without
aﬀecting total or plasmamembrane CXCR4 expression. (A) Aliquots
of the Folch’s upper phases, corresponding to equal amounts of
protein, from control CHP-100 cells (lane 2) or from cells cultured for
5 d in the presence of 0.5 lM PPPP (lane 3), were analyzed for
gangliosides. Lane 1 shows the migration of authentic ganglioside
standards. Ganglioside nomenclature is that of Svennerholm [26]. (B)
Aliquots of the Folch’s lower phases corresponding to equal amounts
of protein, from control CHP-100 cells (lane 1) or from cells cultured
for 5 d in the presence of 0.5 lM PPPP (lane 2), were analyzed for
neutral GSLs. Migration of GalCer and GlcCer standards are shown
in lanes 3 and 4, respectively; lane 5 shows the migration of LacCer
and Gb3 standards. (C) Equal amounts of protein from lysates of
control CHP-100 cells or cells grown for 5 d in the presence of 0.5 lM
PPPP were analyzed by Western Blot for CXCR4 expression. (D)
Surface CXCR4 expression, as monitored by FACS analysis, in
control CHP-100 cells (upper panel) or cells grown for 5 d in the
presence of 0.5 lM PPPP (lower panel), using a phycoerythrin-
conjugated anti-CXCR4 antibody (a-CXCR4-PE), as reported in the
text. Cell autoﬂuorescence is also shown (Baseline).
Fig. 2. GSL depletion inhibits CXCL12-induced cell migration but not
Ca2+ mobilization. CHP-100 cells, either left untreated (None) or
pretreated for 5 d with 0.5 lM PPPP (PPPP) were subjected to
chemotaxis assay either in the absence (Vehicle) or presence of a 60 nM
CXCL12 gradient (CXCL12). PPPP (0.5 lM) was always present in
the medium of PPPP-pretreated cells, whereas migration of untreated
CHP-100 cells was performed either in the absence () or presence (+)
of 0.5 lM PPPP. Data are normalized setting at 100 the number of
control CHP-100 cells migrating in the absence of both CXCL12 and
PPPP in the assay medium (basal) and are expressed as means and S.D.
from four diﬀerent experiments. Statistical signiﬁcance is indicated by
asterisks (P < 0.01, as compared to basal, after Student’s t test). (B)
Representative Ca2+ transients induced by addition of 60 nM CXCL12
(arrows) in CHP-100 cells either left untreated (Control) or pretreated
for 5 d with 0.5 lM PPPP (PPPP) (C) Histograms of the maximal
amplitude of Ca2+ transients induced by 60 nM CXCL12 in CHP-100
cells either left untreated (Control) or pretreated for 5 d with 0.5 lM
PPPP (PPPP). Data are means and S.D. from seven diﬀerent deter-
minations.
C. Limatola et al. / FEBS Letters 581 (2007) 2641–2646 2643long-term treatment with PPPP had no secondary eﬀects on
the levels of cellular cholesterol, whose downregulation has
been reported to inhibit CXCR4-dependent chemotaxis [12]:
cholesterol was in fact estimated 30.9 ± 1.6 lg/mg protein in
control cells (n = 3) and. 30.5 ± 1.6 lg/mg protein in GSL-de-
pleted cell (n = 3).
We found that treatment of CHP-100 cells with 0.5 lM
PPPP for 5 d had no eﬀect on their viability and gross mor-
phology (not shown); moreover, general GSL depletion did
not aﬀect total (Fig. 1C) or plasmamembrane (Fig. 1D)
CXCR4 levels. On the basis of these results, we tested the abil-
ity of control CHP-100 cells and cells treated for 5 d with
0.5 lM PPPP to migrate along a 60 nM CXCL12 gradient,
over a 5-h period. Fig. 2A shows that the extent of basal (i.e.
chemokine-independent) migration was the same in control
CHP-100 cells and the GSL-depleted counterpart. However,
while exposure to the CXCL12 gradient fairly doubled the
amount of migrating control cells, as compared to basal,
CXCL12-induced migration was fully suppressed in GSL-de-
pleted cells. To prevent GSL-depleted cells from resuming
GSL synthesis, their migration test had to be performed in
the presence of 0.5 lM PPPP. Therefore, a further controlhad to be introduced, namely CHP-100 cells not previously ex-
posed to the GCS inhibitor but migrating in the presence of
0.5 lM PPPP. As shown in Fig. 2A, the presence of PPPP
did not aﬀect CXCL12-induced migration in CHP-100 cells
not previously depleted of GSLs.
A signalling pathway associated with CXCR4 stimulation,
but only seldomly related to chemotaxis induction [5], involves
Ca2+ mobilization driven by phospholipase C-b activation.
Therefore, to address the possibility that GSL depletion might
generally compromise CXCR4 function, we studied whether
general GSL downregulation also aﬀected [Ca2+]i variations
induced by CXCL12 (60 nM). In this respect, no signiﬁcant
diﬀerence in the number of responsive elements was found be-
tween control CHP-100 cells (66 ± 13%, n = 25) and the GSL-
depleted counterpart (52 ± 1.6%, n = 27). Moreover, neither
the time course of CXCL12-induced Ca2+ transients
(Fig. 2B), nor their amplitude (Fig. 2C) were aﬀected by
GSL depletion.
Fig. 3. Dependence of inhibition of CXCL12-induced chemotaxis and
GSL downregulation on the time of cell pretreatment with PPPP. (A)
Untreated CHP-100 cells or cells preincubated for the indicated times
with 0.5 lM PPPP were subjected to chemotaxis assay, either in the
absence or presence of a 60 nM CXCL12 gradient, in media containing
0.5 lM PPPP. The chemotactic index (i.e. the ratio of the number of
cells migrated in the presence of CXCL12 to the number of cells
migrated in the absence of CXCL12) was calculated for each time of
preincubation with PPPP. Data are means and S.D. from ﬁve diﬀerent
experiments. Statistical signiﬁcance is indicated by asterisks (P < 0.01,
as compared to cells not preincubated with PPPP, after Student’s t
test). (B) Relative changes of neutral GSL levels, as detected by
densitometric analysis after HPTLC separation, in cells incubated with
0.5 lM PPPP for the indicated times. Data are means and S.D. from
four diﬀerent determinations. Statistical signiﬁcance is indicated by
asterisks (P < 0.01, as compared to cells not preincubated with PPPP,
after Student’s t test). (C) Relative changes of ganglioside levels, as
detected by densitometric analysis after HPTLC separation, in cells
incubated with 0.5 lM PPPP for the indicated times. S.D.s, not shown
for sake of clarity, never exceeded 15% of the mean values, as obtained
from four diﬀerent determinations. Statistically signiﬁcant decrease of
the levels of all ganglioside species, as observed after 24 h of cell
incubation with PPPP, is indicated by the asterisk after the bracket
(P < 0.01, as compared to cells not preincubated with PPPP, after
Student’s t test).
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CXCL12-induced chemotaxis and GSL downregulation
To assess whether general GSL depletion, as observed after
5 d of cell treatment with PPPP, was a stringent requirement
for inhibition of CXCR4-dependent chemotaxis, in a subse-
quent set of experiments CHP-100 cells were preincubated
with 0.5 lM PPPP for shorter times, prior to test their ability
to migrate along a 60 nM CXCL12 gradient. Remarkably, we
found that inhibition of CXCR4-dependent cell migration
started to be observed after relatively short times of pretreat-
ment with the GCS inhibitor. In this respect, Fig. 3A shows
that attenuation of CXCR4-dependent chemotaxis was
clearly observed after 4–5 h of cell pretreatment with the
GCS inhibitor. Moreover, preincubation with 0.5 lM PPPP
for 10 h already produced a pronounced inhibition of
CXCL12-induced cell migration, that turned maximal by
24 h (Fig. 3A).
Based on the results reported above, we studied the kinetics
of GSL downregulation caused by cell exposure to the GCS
inhibitor over a 24 h period. Densitometric analysis after
HPTLC separation indicated that GlcCer level was rapidly
and dramatically downregulated within the time-period exam-
ined, already decreasing to a 30% of its initial value after cell
exposure for 10 h to PPPP, and to about 15% after 24 h
(Fig. 3B). LacCer and Gb3 were also markedly downregulated,
albeit less pronouncedly than GlcCer (Fig. 3B). A somewhat
diﬀerent response was observed for gangliosides, whose levels
were scarcely aﬀected by cell treatment with 0.5 lM PPPP
within 10 h, being however downregulated to a 60–70% of
their initial values, upon prolonging the incubation to 24 h
(Fig. 3C).Fig. 4. Inhibition of CXCL12-induced cell migration after PPPP
pretreatment is reversed by exogenous GSLs. CHP-100 cells pretreated
for 24 h with 0.5 lM PPPP (+) or left untreated () were subjected to
chemotaxis assay either in the presence (+) or absence () of a 60 nM
CXCL12 gradient. Migration tests were performed in the presence of
40 lM C8-GlcCer or 40 lM C8-LacCer or 50 lM ganglioside GM2, or
in the absence of any exogenously added GSL (None), as indicated in
the upper part of the ﬁgure. Media of all samples contained 0.5 lM
PPPP, during the migration test. Data are means and S.D. from four
diﬀerent experiments. Statistical signiﬁcance is indicated by asterisks
(P < 0.02, as compared to the counterparts migrating in the absence of
CXCL12).
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after delivery of exogenous GSLs
To achieve evidence for a causal relationship between GSL
depletion and inhibition of chemokine-dependent cell migra-
tion, we studied whether PPPP-treated CHP-100 cells were
able to resume chemotaxis after addition of exogenous C8-Glc-
Cer or C8-LacCer, two synthetic and short-chain neutral GSL
analogues; moreover, we monitored the eﬀects of exogenously
administered GM2, namely the major ganglioside species in
CHP-100 cells, on the phenomenon. To this aim, cells were
pretreated for 24 h with PPPP and then exposed to a 60 nM
CXCL12 gradient for 5 h in media enriched with the individual
above-mentioned GSL species. As reported in Fig. 4, we ob-
served that all the exogenously administered GSLs were able
to restore the chemotactic response to CXCL12 in PPPP-trea-
ted cells.4. Discussion
Results reported above provide evidence, for the ﬁrst time,
that GSL downregulation, achieved by pharmacological
GCS inhibition, associates with inhibition of CXCL12-induced
chemotaxis. The following lines of evidence support the view
that the above-mentioned outcome, as observed in human
CHP-100 neuroepithelioma cells, is not due to unspeciﬁc ef-
fects of the GCS inhibitor employed but may truly reﬂect a
role for GSLs in sustaining chemokine-induced cell migration.
First, we have reported that, even after long-term treatment
with PPPP, cell viability was not aﬀected; moreover, CXCR4
functional state was preserved, as shown by the evidence that
GSL-depleted cells normally mobilize Ca2+ in response to
stimulation with CXCL12. Second, we have shown that sus-
tained GCS inhibition had no secondary eﬀects on the levels
of cholesterol, whose downregulation has been previously
demonstrated to inhibit CXCR4-dependent chemotaxis [12],
or on those of ceramide, a pleiotropic active lipid [23]. Third,
we have demonstrated that the eﬀect of PPPP on CXCL12-in-
duced chemotaxis was dependent on the time of cell pre-expo-
sure to the GCS inhibitor and correlated with downregulation
of GSL levels; moreover, addition of exogenous GSLs to
PPPP-treated cells restored chemokine-dependent cell migra-
tion.
Indeed, with respect to the latter point, a ﬁnding that de-
serves clariﬁcation deals with the observation that, although
inhibition of CXCR4-dependent cell migration was already
observed when gangliosides were not yet substantially down-
regulated, resumption of chemokine-induced chemotaxis could
be induced not only by exogenous GlcCer and LacCer, but
also by ganglioside GM2. On the one hand, this result would
suggest a redundant function for diﬀerent GSL species in sus-
taining chemokine-induced chemotaxis; thus, one could envis-
age the possibility that the average level of total GSLs, rather
than the level of any particular GSL species, is critical for sus-
taining CXCL12-evoked cell migration. On the other hand,
what remains to be investigated is whether exogenously admin-
istered gangliosides undergo metabolism after their uptake,
possibly leading to enrichment of the pool of (a) neutral
GSL species, critical for chemotaxis occurrence. In this respect,
it might be of particular relevance the notion that ganglioside
catabolism along the salvage pathway may lead to generationof neutral GSLs, particularly GlcCer, that are recycled after
escaping lysosomes [24,25]. Studies are currently in progress
to clarify this point, not only in CHP-100 cells but also in
U87MG human glioblastoma cells, that we also found to re-
spond to PPPP treatment with inhibition of CXCR4-depen-
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